Review of daclizumab and its therapeutic potential in the treatment of relapsing–remitting multiple sclerosis

por Reardon, Jennifer, Perumal, Jai S
Publicado 2013

Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis

por Babij, Rachel, Perumal, Jai S
Publicado 2015

Disease exacerbation after rituximab induction in neuromyelitis optica

por Perumal, Jai S., Kister, Ilya, Howard, Jonathan, Herbert, Joseph
Publicado 2015

A study of patients with aggressive multiple sclerosis at disease onset

por Kaunzner, Ulrike W, Kumar, Gaurav, Askin, Gulce, Gauthier, Susan A, Nealon, Nancy N, Vartanian, Timothy, Perumal, Jai S
Publicado 2016

Long-Term Effectiveness and Safety of Natalizumab in African American and Hispanic/Latino Patients with Early Relapsing–Remitting Multiple Sclerosis: STRIVE Data Analysis

por Perumal, Jai, Balabanov, Roumen, Balcer, Laura, Galetta, Steven, Sun, Zhaonan, Li, Hanyue, Rutledge, Danette, Avila, Robin L., Fox, Robert J.
Publicado 2023

Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE

por Perumal, Jai, Fox, Robert J., Balabanov, Roumen, Balcer, Laura J., Galetta, Steven, Makh, Shavy, Santra, Sourav, Hotermans, Christophe, Lee, Lily
Publicado 2019

Correction to: Improvements in Cognitive Processing Speed, Disability, and Patient‑Reported Outcomes in Patients with Early Relapsing‑Remitting Multiple Sclerosis Treated with Nata...

por Perumal, Jai, Balabanov, Roumen, Su, Ray, Chang, Roger, Balcer, Laura J., Galetta, Steven L., Avila, Robin L., Rutledge, Danette, Fox, Robert J.
Publicado 2023

Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Result...

por Perumal, Jai, Balabanov, Roumen, Su, Ray, Chang, Roger, Balcer, Laura J., Galetta, Steven L., Avila, Robin L., Rutledge, Danette, Fox, Robert J.
Publicado 2022

Black African and Latino/a identity correlates with increased plasmablasts in MS

por Telesford, Kiel M., Kaunzner, Ulrike W., Perumal, Jai, Gauthier, Susan A., Wu, Xian, Diaz, Ivan, Kruse-Hoyer, Mason, Engel, Casey, Marcille, Melanie, Vartanian, Timothy
Publicado 2019

Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study

por Perumal, Jai, Balabanov, Roumen, Su, Ray, Chang, Roger, Balcer, Laura, Galetta, Steven, Campagnolo, Denise I., Avila, Robin, Lee, Lily, Rutledge, Danette, Fox, Robert J.
Publicado 2021

Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study

por Perumal, Jai, Balabanov, Roumen, Su, Ray, Chang, Roger, Balcer, Laura, Galetta, Steven, Campagnolo, Denise I., Avila, Robin, Lee, Lily, Rutledge, Danette, Fox, Robert J.
Publicado 2021

Disease correlates of rim lesions on quantitative susceptibility mapping in multiple sclerosis

por Marcille, Melanie, Hurtado Rúa, Sandra, Tyshkov, Charles, Jaywant, Abhishek, Comunale, Joseph, Kaunzner, Ulrike W., Nealon, Nancy, Perumal, Jai S., Zexter, Lily, Zinger, Nicole, Bruvik, Olivia, Wang, Yi, Sweeney, Elizabeth, Kuceyeski, Amy, Nguyen, Thanh D., Gauthier, Susan A.
Publicado 2022

Epsilon toxin–producing Clostridium perfringens colonize the multiple sclerosis gut microbiome overcoming CNS immune privilege

por Ma, Yinghua, Sannino, David, Linden, Jennifer R., Haigh, Sylvia, Zhao, Baohua, Grigg, John B., Zumbo, Paul, Dündar, Friederike, Butler, Daniel, Profaci, Caterina P., Telesford, Kiel, Winokur, Paige N., Rumah, Kareem R., Gauthier, Susan A., Fischetti, Vincent A., McClane, Bruce A., Uzal, Francisco A., Zexter, Lily, Mazzucco, Michael, Rudick, Richard, Danko, David, Balmuth, Evan, Nealon, Nancy, Perumal, Jai, Kaunzner, Ulrike, Brito, Ilana L., Chen, Zhengming, Xiang, Jenny Z., Betel, Doron, Daneman, Richard, Sonnenberg, Gregory F., Mason, Christopher E., Vartanian, Timothy
Publicado 2023